New drug cocktail CKD-215 tested in ovarian cancer patients
NCT ID NCT07532148
First seen May 01, 2026 · Last updated May 01, 2026
Summary
This early-stage study compares two drug formulations (CKD-215 and D215) in 24 adults with advanced BRCA-mutated ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how the body processes each drug and check for side effects. Participants will receive both treatments in a random order to find the safest and most effective option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.